University of Maryland Medical Center

Marlene and Stewart Greenebaum Comprehensive Cancer Center

Baltimore, MD

Sorting 8 by

Accepting patients

MonumenTAL-6

A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
  • Bispecific Antibody
  • CD3
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

DREAMM13

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Accepting patients

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1

Not yet accepting

IGI 10% (TAK-339)

A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy
  • Randomization
  • Phase 3

Accepting patients

iMMagine-3

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • Randomization
  • Phase 3

Accepting patients

P-BCMA-ALLO1

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Has results

Not currently accepting

MajesTEC-4

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
  • Bispecific Antibody
  • BCMA
  • Phase 3